EHA25 Virtual Become a subscriber and gain exclusive access to biotech's biggest events Join Today It's your journey. Request a Research Report Make it personal. Sign Up For Our Newsletter Keep Up To date On the latest insights and research from clover biotech research Join Now!

Experience The Difference


We’re here to assist you with any matter. You can always count on a reply from us within 48 hours.

Exclusive Content

Count on unprecedented live and exclusive coverage to biotechnology’s greatest events (e.g. ASCO annual meeting).

Membership Perks

We value your support! Annual members will be eligible to receive discounts on products and prizes in excess of $100!

Quality Content

Content you can trust! Our articles will always include trusted and relevant source(s) (e.g. journal articles).


Our website is protected with the standard encryption techniques (SHA-1 with RSA) utilized by companies like Netflix and Disney.

Ad-Free Content

You can actually turn off your ad blocker for a change! Our website can be the one place you can escape from toenail fungus ads.

Frontline Insight

As a practicing critical care registered nurse, you can be sure I am reporting directly from the frontlines of health and medicine.

Personalized Content

Available for Prime members at no cost, we will write a well-referenced, 2500-word biotech research report on your topic of choice!

Focused Content

Investing can be overwhelming! That’s why our content is focused only on the couple of dozen biotechs I find most promising.


Your coins are safe with us! All payments made on this site are processed through trusted third-party applications like Amazon & Stripe.

Get Access


Includes access to focused content, a community/author-supported Live Chat, & exclusive product discounts

Includes Basic privileges, access to comprehensive research reports, and exclusive membership perks
Includes Plus privileges, live/exclusive conference coverage (two-plus/year), & one personalized research report

Become Enlightened

Blueprint Medicines: Unleashing A “New Era In The Management” Of ASM (EHA Preview)

Note: For more research and insights like this, please consider supporting Clover Biotech Research and subscribe today (10-day free trial). Summary: Blueprint Medicines plans to reveal updated data for advanced systemic mastocytosis (ASM) When compared to current standard of care for ASM, Blueprint’s avapritinib appears to provide improved efficacy across many measures EHA25 data is

Read more

From Abandonment To Resurrection: A Look Into Xenon’s Phase 3-Ready Drug For KCNQ2-EE

Summary: Xenon Pharmaceuticals recently announced they will proceed with a pivotal, phase 3 study for their repurposed drug, XEN496, in KCNQ2-EE The repurposing of retigabine, along with the development of other anti-epileptic drugs, represented a shift in company focus following two major trial failures in 2015 (pain) and 2017 (acne) Backed with solid clinical rationale To access this post, you must purchase Prime Membership, Basic Membership or Plus Membership...

Read more

Arvinas’ ASCO Abstract Data May Have Been Misunderstood

Summary: Arvinas recently revealed their ASCO abstract which included first-in-human efficacy and safety data for their leading drug, ARV-110. The initial market response was negative (ARVN -25%) but the data appears to have been widely misinterpreted secondary to high expectations. ARV-110, as monotherapy, induced a 25% (2/8) response rate in doses shown to be tumor-inhibiting To access this post, you must purchase Prime Membership...

Read more

Aurinia: Navigating Voclosporin’s Prospects In Lupus Nephritis (Membership Required)

Summary: There does not yet appear to be definite, high-quality evidence that voclosporin is really attenuating active Lupus Nephritis (LN). These concerns could have been easily laid to rest had the company simply performed renal biopsies post-treatment. But like drops of water, biotechnology companies are typically only willing to move in directions of least resistance. To access this post, you must purchase Prime Membership, Basic Membership or Plus Membership...

Read more

This information is protected.